Who are Vikasolum's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eabeth, AO-128, Pieceid, Buphenyl, ranirestat, (AS-3201), AT-007.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/menadione-sodium-bisulfite.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vikasolum — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vikasolum (MENADIONE SODIUM BISULFITE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Hematology.

phase 2 Aldose reductase Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Vikasolum (MENADIONE SODIUM BISULFITE). Vikasolum works by interacting with and stabilizing vitamin K-dependent proteins in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vikasolum TARGET	MENADIONE SODIUM BISULFITE		phase 2		Aldose reductase
Eabeth	EPALRESTAT		marketed	epalrestat	Aldose reductase	1992-01-01
AO-128	AO-128	Takeda	marketed	Aldose reductase inhibitor	Aldose reductase
Pieceid	polydatin		marketed	pieceid	Glucose-6-phosphate 1-dehydrogenase, Aldose reductase
Buphenyl	Buphenyl	Amgen	marketed		Aldose reductase, Histone deacetylase 1, Histone deacetylase 2
ranirestat, (AS-3201)	ranirestat, (AS-3201)	Sumitomo Pharma Co., Ltd.	phase 3	Aldose reductase inhibitor	Aldose reductase
AT-007	AT-007	Applied Therapeutics, Inc.	phase 3	Aldose reductase inhibitor	Aldose reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vikasolum — Competitive Intelligence Brief. https://druglandscape.com/ci/menadione-sodium-bisulfite. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing